Kisspeptin-10

Kisspeptin-10 is the shortest biologically active fragment of the kisspeptin family of neuropeptides, encoded by the KISS1 gene. The KISS1 gene was originally identified as a metastasis suppressor in melanoma, but its endocrine role was established when researchers discovered that kisspeptin neurons in the hypothalamus serve as master regulators of the reproductive hormone axis. Kisspeptin-10 specifically refers to the 10-amino acid C-terminal fragment (Tyr-Asn-Trp-Asn-Ser-Phe-Gly-Leu-Arg-Phe-NH2) that retains full receptor binding activity. It acts through the G-protein coupled receptor GPR54 (also called KISS1R), which is expressed primarily on gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus.

The mechanistic cascade initiated by Kisspeptin-10 binding to GPR54 is well characterized. Receptor activation triggers the release of GnRH in pulsatile bursts, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In men, LH drives Leydig cell production of testosterone; in women, the LH surge triggers ovulation and supports progesterone synthesis. This makes Kisspeptin-10 a proximal upstream activator of the entire gonadal hormone axis. Importantly, kisspeptin neurons integrate multiple peripheral signals (including leptin, estradiol, and metabolic status) into a single output: the GnRH pulse. This positions kisspeptin as a physiological gatekeeper of reproductive function responsive to body composition and nutritional state.

Human clinical research on Kisspeptin-10 is more robust than for many research peptides. A landmark study published in the Journal of Clinical Endocrinology and Metabolism found that intravenous bolus doses of Kisspeptin-10 produced a rapid, dose-dependent rise in LH concentration, with maximal stimulation at 1 mcg/kg. Continuous IV infusion at 4 mcg/kg/hour for 22.5 hours raised mean LH significantly and increased serum testosterone from 16.6 to 24.0 nmol/L in healthy men. A lower dose infusion at 1.5 mcg/kg/hour increased LH pulse frequency from 0.7 to 1.0 pulses per hour. Additional research in men with type 2 diabetes and mild hypogonadism found that Kisspeptin-10 stimulated LH and testosterone secretion even in men with blunted baseline hormone output. Research at Imperial College London also found that kisspeptin administration increased activation in brain regions associated with sexual arousal, attraction, and olfactory cues in male volunteers, suggesting direct CNS effects beyond the hypothalamic-pituitary axis.

Kisspeptin-10 research is particularly interesting in the context of hypothalamic amenorrhea (loss of menstrual function due to low body weight or stress), functional hypogonadotropic hypogonadism, and infertility. Unlike exogenous testosterone or gonadotropins, Kisspeptin-10 works by restoring the natural pulsatile signaling architecture rather than replacing downstream hormones. This makes it theoretically attractive as a means to preserve testicular or ovarian function and avoid the HPTA suppression associated with exogenous hormone use.